Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994926 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment
A Early Phase 1 study, sponsored by Battelle Memorial Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT03994926: Clinical Trial Early Phase 1 study, sponsored by Battelle Memorial Institute.
NCT03994926 is a Early Phase 1 study that was terminated before completion, run by Battelle Memorial Institute. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03994926, a Early Phase 1 study, was terminated before completion, sponsored by Battelle Memorial Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self-reported cannabis subjective effects, cognitive effects).
Primary Outcome
Change in pupil dilation in different lights will be measured by the eye tracking sensor
Interventions
- DEVICE Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye
- DRUG Cannabis cigarette - 4.0% THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2020-03-13 |
| Phase | Early Phase 1 |
Why NCT03994926 stopped before completion
NCT03994926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye is the first listed.
NCT03994926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03994926 about?
NCT03994926 is a clinical study titled "Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment". The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self...
What is the current status of trial NCT03994926?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-03. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT03994926?
The interventions under investigation include: Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye (DEVICE), Cannabis cigarette - 4.0% THC (DRUG).
Who is sponsoring clinical trial NCT03994926?
This trial is sponsored by Battelle Memorial Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03994926's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI